<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03185481</url>
  </required_header>
  <id_info>
    <org_study_id>B7601017</org_study_id>
    <secondary_id>2017-000128-81</secondary_id>
    <nct_id>NCT03185481</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations</brief_title>
  <official_title>A Phase 2, Open Label Extension Study To Investigate The Long Term Safety And Tolerability Of Pf-06649751 In Subjects With Motor Fluctuations Due To Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the long term safety and tolerability of PF-06649751
      in Parkinson's disease patients who experience motor-fluctuations.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open label study evaluating the long term safety and tolerability of PF-06649751
      in Parkinson's disease patients who experience motor-fluctuations. Subjects who completed Ph2
      study B7601003 will be randomized to one of 4 treatment groups (15 mg QD, 7 mg QD, 3 mg QD,
      or 1 mg QD group) depending on the treatment received in B7601003 and titrated up to 15 mg QD
      over a 3 week period, as appropriate. All subjects who were blindly down-titrated during the
      B7601003 study will remain at/or be titrated to 7 mg QD only and remain at that dose for the
      rest of the B7601017 study in order to protect the blind for the prior study. Subjects who
      successfully titrate to 15 mg QD will enter the Adjustment Period at that dose.

      Subjects who cannot tolerate 15 mg QD at any time during the study will be allowed to
      down-titrate to 7 mg QD (but not lower) and will stay at that dose for the rest of the study.

      Subjects who cannot remain at a stable dose (7 mg or 15 mg QD) will be discontinued.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Terminated 25Sep17 due to parent study insufficient efficacy. Not due to safety
  </why_stopped>
  <start_date type="Actual">July 6, 2017</start_date>
  <completion_date type="Actual">October 24, 2017</completion_date>
  <primary_completion_date type="Actual">October 24, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Depending on the actual treatment the subject received in B7601003, subjects will be randomized to one of 4 treatment groups (15 mg QD, 7 mg QD, 3 mg QD, or 1 mg QD group) and titrated up to 15 mg QD over a 3 week period, as appropriate.
All subjects who were blindly down-titrated during the parent study (B7601003) will remain at/or be titrated to 7 mg QD only and remain at that dose for the rest of the B7601017 study in order to protect the blind for the parent study. Subjects who successfully titrate to 15 mg QD will enter the Adjustment Period at that dose. Subjects who cannot tolerate 15 mg QD at any time during the study will be allowed to down-titrate to 7 mg QD (but not lower) and will stay at that dose for the rest of the study. Subjects who cannot remain at a stable dose (7 mg or 15 mg QD) will be discontinued.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>During the titration phase, the allocation to treatment will be double blind to protect the blind of the parent study (B7601003). After completing the titration phase, the treatment assignment becomes open label.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability including AEs, Clinical laboratory, Vital signs, and ECG.</measure>
    <time_frame>From Randomization to Month 12</time_frame>
    <description>Includes:
Adverse events; Physical and neurological examination findings; Clinical laboratory parameters findings; Vital signs findings; Electrocardiogram (ECG) parameter findings; Columbia Suicidality Severity Rating Scale (C-SSRS) findings; Physician Withdrawal Checklist (PWC-20) findings.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Daily OFF time (hours)</measure>
    <time_frame>From Baseline to Month 12</time_frame>
    <description>Change from baseline in Daily OFF time (hours)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Daily ON time with troublesome dyskinesia (hours)</measure>
    <time_frame>From Baseline to month 12</time_frame>
    <description>Change from baseline in Daily ON time with troublesome dyskinesia (hours)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Daily ON time without troublesome dyskinesia (hours)</measure>
    <time_frame>From Baseline to Month 12</time_frame>
    <description>Change from baseline in Daily ON time without troublesome dyskinesia (hours)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in MDS-UPDRS Parts I, II, III, IV, and total score</measure>
    <time_frame>From Baseline to Month 12</time_frame>
    <description>Change from baseline in MDS-UPDRS Parts I, II, III, IV, and total score</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Parkinson's Disease With Motor Fluctuations</condition>
  <arm_group>
    <arm_group_label>1 mg QD to 15 mg QD PF-06649751</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up titration from 1 mg QD to 15 mg QD PF-06649751</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 mg QD to 15 mg QD PF-06649751</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up titration from 3 mg QD to 15 mg QD PF-06649751</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7 mg QD to 15 mg QD PF-06649751</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up titration from 7 mg QD to 15 mg QD PF-06649751</description>
  </arm_group>
  <arm_group>
    <arm_group_label>15 mg QD PF-06649751</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 mg QD PF-06649751 remains at 15 mg QD PF-06649751</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1 mg to 7 mg QD PF-06649751</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up titration from 1 to 7 mg QD PF-06649751 if de-escalated in parent study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 mg QD to 7 mg QD PF-06649751</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up titration from 3 to 7 mg QD PF-06649751 if de-escalated in parent study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7 mg QD to 7 mg QD PF-06649751</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>7 mg QD remains at 7 mg QD PF-06649751 if de-escalated in parent study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>15 mg to 7 mg QD PF-06649751</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 mg QD de-escalated to 7 mg QD in parent study B7601003 remain at 15 mg QD PF-06649751</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1 mg QD to 15 mg QD PF-06649751</intervention_name>
    <description>Up titration from 1 mg QD to 15 mg QD PF-06649751</description>
    <arm_group_label>1 mg QD to 15 mg QD PF-06649751</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3 mg QD to 15 mg QD PF-06649751</intervention_name>
    <description>Up titration from 3 mg QD to 15 mg QD PF-06649751</description>
    <arm_group_label>3 mg QD to 15 mg QD PF-06649751</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>7 mg QD to 15 mg QD PF-06649751</intervention_name>
    <description>Up titration from 7 mg QD to 15 mg QD PF-06649751</description>
    <arm_group_label>7 mg QD to 15 mg QD PF-06649751</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>15 mg QD PF-06649751</intervention_name>
    <description>15 mg QD PF-06649751 remaining at 15 mg QD PF-06649751</description>
    <arm_group_label>15 mg QD PF-06649751</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1 mg QD to 7 mg QD PF-06649751 (if de-escalated in parent study)</intervention_name>
    <description>Up titration from 1 mg QD to 7 mg QD PF-06649751 for subject at 1 mg QD who were blindly de-escalated in the parent study</description>
    <arm_group_label>1 mg to 7 mg QD PF-06649751</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study)</intervention_name>
    <description>Up titration from 3 mg QD to 7 mg QD PF-06649751 for 3 mg QD subjects who were blindly de-escalated in parent study</description>
    <arm_group_label>3 mg QD to 7 mg QD PF-06649751</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>7 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study)</intervention_name>
    <description>7 mg QD to remain at 7 mg QD PF-06649751 for subjects who were blindly de-escalated in parent study</description>
    <arm_group_label>7 mg QD to 7 mg QD PF-06649751</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>15 mg QD de-escalated to 7 mg QD PF-06649751 in parent study remain at 7 mg QD</intervention_name>
    <description>7mg QD PF-06649751 for subjects assigned to 15 mg QD who were blindly de-escalated to 7 mg QD PF-06649751 in parent study</description>
    <arm_group_label>15 mg to 7 mg QD PF-06649751</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Having successfully completed parent study B7601003.

          -  Clinical diagnosis of Parkinson's disease.

          -  Able to refrain from any Parkinson's disease medication not permitted by the protocol.

        Exclusion Criteria:

          -  Female of childbearing potential.

          -  Severe acute or chronic medical or psychiatric condition or laboratory abnormality.

          -  Participation in other studies involving investigational drug(s), or treatment with
             any investigational drug within 30 days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>87 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hoag Memorial Hospital Presbyterian</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associated Neurologists of Southern CT, PC</name>
      <address>
        <city>Fairfield</city>
        <state>Connecticut</state>
        <zip>06824</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parkinson's Disease and Movement Disorders Center of Boca Raton</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Center for Medical Research</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30331</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pharmaceutical Research Associates, Inc.</name>
      <address>
        <city>Marlton</city>
        <state>New Jersey</state>
        <zip>08053</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Toledo, Gardner-McMaster Parkinson Center</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Toledo, Investigational Drug Services</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Movement Disorder Clinic of Oklahoma</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Booth Gardner Parkinson's Care Center</name>
      <address>
        <city>Kirkland</city>
        <state>Washington</state>
        <zip>98034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B7601017&amp;StudyName=Phase+2+Open+Label+Extension+Study+To+Investigate+The+Long+Term+Safety+And+Tolerability+Of+Pf-06649751</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B7601017&amp;StudyName=A+Phase+2+Open+Label+Extension+Study+To+Investigate+The+Long+Term+Safety+And+Tolerability+Of+Pf-06649751</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B7601017&amp;StudyName=A+Phase+2%2C+Open+Label+Extension+Study+To+Investigate+The+Long+Term+Safety+And+Tolerability+Of+Pf-06649751+In+Subjects+With+Motor+Fluctuations+Due+To+Parkinson%27s+Disease</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 9, 2017</study_first_submitted>
  <study_first_submitted_qc>June 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2017</study_first_posted>
  <last_update_submitted>December 1, 2017</last_update_submitted>
  <last_update_submitted_qc>December 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson's Disease</keyword>
  <keyword>Motor Fluctuations</keyword>
  <keyword>D1 partial agonist</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

